Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05975684 · ClinicalTrials.gov registry record · Phase 3
Baclofen for Children With Rumination Syndrome
A Phase 3 study of Rumination Syndrome, sponsored by Nationwide Children's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05975684 is a Phase 3 study of Rumination Syndrome that has completed, run by Nationwide Children's Hospital. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05975684, a Phase 3 study of Rumination Syndrome, has completed, sponsored by Nationwide Children's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about baclofen in pediatric patients with rumination syndrome. The main question it aims to answer is whether baclofen is effective in treating children with rumination syndrome. Participants will be asked to take baclofen or placebo for 4 weeks and fill out surveys regarding symptoms.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Baclofen
Study Locations (1)
Ohio
- Nationwide Children's Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-01-31 |
| Est. Completion | 2025-01-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05975684
The ClinicalTrials.gov registry entry for NCT05975684 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rumination Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05975684 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05975684 about?
NCT05975684 is a clinical study titled "Baclofen for Children With Rumination Syndrome". The goal of this clinical trial is to learn about baclofen in pediatric patients with rumination syndrome. The main question it aims to answer is whether baclofen is effective in treating children with rumination syndrome. Participants will be asked to take baclofen or placebo for 4 weeks and fill o...
What is the current status of trial NCT05975684?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2023-01-31. Estimated completion is 2025-01-27.
What conditions does trial NCT05975684 study?
This clinical trial studies the following conditions: Rumination Syndrome.
What interventions are being tested in trial NCT05975684?
The interventions under investigation include: Placebo (DRUG), Baclofen (DRUG).
Who is sponsoring clinical trial NCT05975684?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05975684 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.